Thursday, Feb 27th, 2020
Crowne Plaza Times Square, New York City, NY
Mechanisms and Biomarkers of Resistance in the Era of IO Combination Therapy
Panel Title: Mechanisms and Biomarkers of Resistance in the Era of IO Combination Therapy
Moderator: Priti Hegde, Ph.D. (CSO at Foundation Medicine)
Panelists: Robert Georgantas III, Ph.D. (SVP, Research & Translational Science at Biodesix), Ian McCaffery, Ph.D. (VP, Oncology Translational Science at Janssen), and Alexandra Snyder, MD (Head, Translational Oncology at Merck Research Labs)
Discussion: Given the number of combination therapies that are ongoing, one of the ways in which one can prioritize combinations is by assessing the translatability of the preclinical biology into the clinic. We do realize there are challenges associated with this including biological translation and challenges with the tools and technologies available for us to assess biology robustly in patients. This panel will discuss where we stand today, identify the key challenges we are facing and explore the opportunities we have to address those gaps.